Evolus, Inc. (EOLS)
Data as of , from SEC Form 4 filings.
See up to 3 months of EOLS. The 7-day demo opens the 1M and 3M ranges and puts EOLS on your watchlist.
Start 7-day demoLatest EOLS insider trades
About Evolus, Inc. (EOLS)
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
- NEWPORT BEACH, CA
- 353
- 2018
- XNAS
EOLS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 105,108 | $950K |
EOLS insider transactions (Form 4)
3019 Form 4 filings on record, the earliest from Dec 26, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Moatazedi - Officer | Open-market sale | Common Stock | 105,108 | $9.04 footnote F1 | $950K | |
| ||||||
| Rui Avelar - Officer | Open-market sale | Common Stock | 3,119 | $4.75 footnote F2 | $15K | |
| ||||||
| David Moatazedi - Officer | Open-market sale | Common Stock | 13,669 | $4.75 footnote F2 | $65K | |
| ||||||
| David Moatazedi - Officer | Option exercise | Common Stock | 67,489 | $0.00 | - | |
| David Moatazedi - Officer | Open-market sale | Common Stock | 116,720 | $4.89 footnote F3 | $571K | |
| David Moatazedi - Officer | Option exercise | Performance Restricted Stock Units | 67,489 | $0.00 | - | |
| ||||||
| Rui Avelar - Officer | Option exercise | Common Stock | 8,804 | $0.00 | - | |
| Rui Avelar - Officer | Open-market sale | Common Stock | 29,996 | $4.89 footnote F3 | $147K | |
| Rui Avelar - Officer | Option exercise | Performance Restricted Stock Units | 8,804 | $0.00 | - | |
| ||||||
 Karah Herdman Parschauer - Director | Grant or award | Common Stock | 45,559 footnote F1 | $0.00 | - | |
| ||||||
| Brady Stewart - Director | Grant or award | Common Stock | 45,559 footnote F1 | $0.00 | - | |
| ||||||
 Tatjana Mitchell - Officer | Grant or award | Common Stock | 121,489 footnote F1 | $0.00 | - | |
| Tatjana Mitchell - Officer | Grant or award | Performance Restricted Stock Units | 121,489 | $0.00 | - | |
| Tatjana Mitchell - Officer | Grant or award | Stock Option (Right to Buy) | 177,471 | $0.00 | - | |
| ||||||
 Albert G. White III - Director | Grant or award | Common Stock | 45,559 footnote F1 | $0.00 | - | |
| ||||||
| David Moatazedi - Officer | Grant or award | Common Stock | 313,212 footnote F1 | $0.00 | - | |
| David Moatazedi - Officer | Grant or award | Performance Restricted Stock Units | 626,424 | $0.00 | - | |
| David Moatazedi - Officer | Grant or award | Stock Option (Right to Buy) | 457,541 | $0.00 | - | |
| ||||||
 Vikram Malik - Director | Grant or award | Common Stock | 45,559 footnote F1 | $0.00 | - | |
| ||||||
| Rui Avelar - Officer | Grant or award | Common Stock | 94,913 footnote F1 | $0.00 | - | |
| Rui Avelar - Officer | Grant or award | Performance Restricted Stock Units | 94,913 | $0.00 | - | |
| Rui Avelar - Officer | Grant or award | Stock Option (Right to Buy) | 138,649 | $0.00 | - | |
| ||||||
| David N. Gill - Director | Grant or award | Common Stock | 45,559 footnote F1 | $0.00 | - | |
| ||||||
| Tatjana Mitchell - Officer | Grant or award | Common Stock | 104,603 | $0.00 | - | |
| Tatjana Mitchell - Officer | Grant or award | Stock Option (Right to Buy) | 143,403 | $0.00 | - | |
| Tomoko Yamagishi-Dressler - Officer | Open-market sale | Common Stock | 5,722 | $7.51 | $43K | |
| Brady Stewart - Director | Open-market purchase | Common Stock | 30,000 | $6.82 | $204K | |
| Sandra Beaver - Officer | Open-market sale | Common Stock | 1,586 | $10.85 | $17K | |
| David Moatazedi - Officer | Open-market sale | Common Stock | 10,502 | $10.85 | $114K | |
| Rui Avelar - Officer | Open-market sale | Common Stock | 2,252 | $10.85 | $24K | |
Item 2.02, 9.01
Item 1.01, 7.01, 9.01
Item 1.01, 7.01, 9.01
Item 5.07
Recent EOLS Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| DAVID MOATAZEDI | Officer, Director | 105,108 | $950K | View on EDGAR |
EOLS insider trading FAQ
What is the latest insider trade for EOLS?
Evolus, Inc. (EOLS) had 1 insider filing in the last 90 days, with the most recent on 2026-09-04. The full record for EOLS runs to 19 Form 4 filings, the earliest from 2024-12-26. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying EOLS stock?
No insider purchases of EOLS were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling EOLS stock?
1 insider sale of EOLS was filed in the last 90 days, totaling $950K.
Where can I see EOLS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects EOLS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - David Moatazedi view on EDGAR
- - Rui Avelar view on EDGAR
- - David Moatazedi view on EDGAR
- - David Moatazedi view on EDGAR
- - Rui Avelar view on EDGAR
- - Karah Herdman Parschauer view on EDGAR
- - Brady Stewart view on EDGAR
- - Tatjana Mitchell view on EDGAR
- - Albert G. White III view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where EOLS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow EOLS with a 7-day demo
- EOLS on your watchlist
- Every EOLS Form 4 filing on record
- Up to 3 months of EOLS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
